This study investigates whether incorporating bone mineral density (BMD) into FRAX calculations changes fracture risk assessment and influences treatment decisions in rheumatoid arthritis (RA) patients. Analyzing 60 RA patients, FRAX scores for 10-year major osteoporotic and hip fractures were calculated with and without BMD. While no significant differences were found between the two methods, discrepancies in treatment recommendations were identified, particularly for hip fractures. The findings emphasize the importance of combining BMD and FRAX for a more comprehensive fracture risk assessment and informed treatment decision-making in RA patients.
Study Type
OBSERVATIONAL
Enrollment
60
No intervention
Istanbul Physical Medicine and Rehabilitation Training and Research Hospital
Istanbul, Bahcelievler, Turkey (Türkiye)
Concordance Between FRAX Scores With and Without BMD
The agreement between 10-year fracture risk calculations for major osteoporotic fractures (MOF) and hip fractures (HF) using FRAX with and without bone mineral density (BMD).
Time frame: 0 day
Treatment Threshold Exceedance Based on FRAX Calculations
Proportion of patients exceeding treatment thresholds for MOF and HF risk based on FRAX calculations with and without BMD.
Time frame: 0 day
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.